G
The work to be performed will involve the continued development, test, evaluation, and final completion of the current prototype assay and will be used in triage for rapidly screening patients infected (symptomatic), as well as provide comfort to those who may believe they potentially have been exposed (symptomatic and asymptomatic) and who may need post-exposure prophylaxis. The RPS FebriDx LFA will mitigate the consequence of biological incidents through early detection and complement the Government's "detect-to-treat" approach by providing a new capability to DHS and its stakeholders that not only rapidly and accurately diagnoses patients at the point of care, but buys precious time for the delivery of requisite medical countermeasures. Therefore, this requested action to continue support to develop, test, evaluate, and complete the current prototype assay will ensure continuity of the Government's ability to mitigate the consequence of biological incidents.
The services to be provided for this proposed sole source action will also offer a solution for the widespread over use of antibiotics (and the resulting increase in antibiotic resistance), and will significantly mitigate the current costs associated with making an accurate diagnosis so that effective treatment can be administered.
Note 22: This pre-award synopsis is for informational purposes only. Technical proposals will not be considered, however technical capability statements may be submitted, only if your organization has the technical capabilities necessary to meet the above stated needs. If such documents are submitted, they may be reviewed for consideration to open this requirement up for competition. The determination to open up the requirement to competition is at the sole discretion of the Government. All submissions become the property of the Federal Government, and will not be returned.